openFDA
Cure8 regulatory brief
ABRILADA FDA label update (2026-08-07)
Medications
Adalimumab
Anti-TNF
Regulatory Update
Adult patients
Pediatric Patients
Clinicians
Crohn's disease
Why This Matters
This is an FDA drug-label record for ABRILADA (an adalimumab product). It confirms that ABRILADA is approved for treating moderately to severely active Crohn’s disease (adults and children 6+) and ulcerative colitis (adults), and it includes major safety warnings that affect people using TNF blockers.
Who Should Pay Attention
People with Crohn’s disease or ulcerative colitis considering or taking adalimumab products; parents/caregivers of pediatric patients (age 6+ for Crohn’s); gastroenterologists and prescribing clinicians; clinicians monitoring immunosuppressed patients.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This DailyMed / FDA drug label update adds and/or confirms indications and safety information for ABRILADA (an adalimumab product). The label lists approved uses including Crohn’s disease (ages 6 and up), ulcerative colitis (adults), and multiple autoimmune conditions, plus boxed warnings about serious infections and malignancy.
The document is a regulatory product label; it summarizes approved indications, limitations of use, and major safety warnings.
Keep In Mind
This is an official FDA/DailyMed labeling document (regulatory-record). It reports approved indications and standard boxed warnings for adalimumab products; it is not a research report or clinical trial result. Patients should discuss label details, risks, and monitoring with their prescribing clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorA-S Medication Solutions
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedAug 7, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ABRILADA FDA label update (2026-06-18)
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
Adalimumab FDA label update (2026-07-08)
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
DailyMed label update for AMJEVITA
An updated drug label for AMJEVITA affects people with Crohn's disease, ulcerative colitis, and other immune conditions because it defines FDA‑approved uses, dosing schedules (including pediatric dosing), and safety...